Everolimus-eluting stents: redefining the risk for very late stent thrombosis.
aDepartment of Cardiology, The Second Affiliated Hospital of Harbin Medical University bThe Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education, Harbin, China.
Jinwei
J
Tian
Bo
B
Yu
D002317:Cardiovascular Agents / Q000008:administration & dosage*; D003324:Coronary Artery Disease / Q000628:therapy*; D003328:Coronary Thrombosis / Q000517:prevention & control*; D054855:Drug-Eluting Stents; D000068338:Everolimus; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage*; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*
D002317:Cardiovascular Agents; D000068338:Everolimus; D017239:Paclitaxel; D020123:Sirolimus